ScinoPharm Taiwan, Ltd.

TWSE:1789 Stock Report

Market Cap: NT$19.0b

ScinoPharm Taiwan Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Susan Lu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3.8yrs
CEO ownershipn/a
Management average tenure4.3yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 17
ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Apr 04
Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Mar 14
A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

Feb 21
Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

Jan 25
ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Jan 04
We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Dec 14
Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Nov 23
Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

CEO

Susan Lu

3.8yrs

Tenure

Ms. Li-An Lu, also known as Susan, is Director of SciAnda (Changshu) Pharmaceutical, Ltd. from June 14, 2024. She serves as President and Chief Executive Officer at ScinoPharm Taiwan, Ltd.since 2021. She...

Leadership Team

NamePositionTenureCompensationOwnership
Chih-Hsien Lo
Chairman & General Chief Strategy Officer14.3yrsno datano data
Li-An Lu
President & CEO3.8yrsno datano data
Chih-Hui Lin
Acting Financial Off.14.4yrsno datano data
Ling-Hsiao Lien
Vice-President of Marketing4.3yrsno datano data
Li-Chiao Chang
VP of R&D Division and Chief Scientific Officerno datano data0%
NT$ 0
Jason Chen
Director of Human Resources & Admin3.4yrsno datano data
Shun Yang Lin
Director of Corporate Developmentno datano datano data

4.3yrs

Average Tenure

Experienced Management: 1789's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chih-Hsien Lo
Chairman & General Chief Strategy Officer14.3yrsno datano data
Po-Ming Hou
Representative Director8yrsno datano data
Fu-Jung Lai
Representative Director6.1yrsno datano data
Shiow-Ling Kao
Representative Director14.3yrsno datano data
Chiou-Ru Shih
Representative Director14.3yrsno datano data
Tsung-Ping Wu
Representative Director9.4yrsno datano data
Jia-Horng Guo
Representative Director7.3yrsno datano data
Li-Tzong Chen
Independent Director6.4yrsno datano data
Ming-Chuan Hsieh
Representative Director6.4yrsno datano data
Ya-Po Yang
Representative Director6.4yrsno datano data
Wen-Chang Chang
Independent Director6.4yrsno datano data
Lewis Lee
Independent Director3.8yrsno datano data

6.8yrs

Average Tenure

Experienced Board: 1789's board of directors are considered experienced (6.8 years average tenure).